LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples